- Home
- STAI vs FGEN Comparison
STAI vs FGEN Comparison
Compare STAI & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STAI
- FGEN
- Stock Information
- Founded
- STAI 2011
- FGEN 1993
- Country
- STAI United States
- FGEN United States
- Employees
- STAI N/A
- FGEN N/A
- Industry
- STAI
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- STAI
- FGEN Health Care
- Exchange
- STAI Nasdaq
- FGEN Nasdaq
- Market Cap
- STAI 36.3M
- FGEN 33.5M
- IPO Year
- STAI N/A
- FGEN 2014
- Fundamental
- Price
- STAI $1.96
- FGEN $0.30
- Analyst Decision
- STAI
- FGEN Strong Buy
- Analyst Count
- STAI 0
- FGEN 1
- Target Price
- STAI N/A
- FGEN $10.00
- AVG Volume (30 Days)
- STAI 802.9K
- FGEN 1.6M
- Earning Date
- STAI 01-01-0001
- FGEN 05-05-2025
- Dividend Yield
- STAI N/A
- FGEN N/A
- EPS Growth
- STAI N/A
- FGEN N/A
- EPS
- STAI N/A
- FGEN N/A
- Revenue
- STAI $522,166.00
- FGEN $29,621,000.00
- Revenue This Year
- STAI N/A
- FGEN $544.98
- Revenue Next Year
- STAI N/A
- FGEN $9.45
- P/E Ratio
- STAI N/A
- FGEN N/A
- Revenue Growth
- STAI N/A
- FGEN N/A
- 52 Week Low
- STAI $1.23
- FGEN $0.18
- 52 Week High
- STAI $12.19
- FGEN $2.33
- Technical
- Relative Strength Index (RSI)
- STAI N/A
- FGEN 38.86
- Support Level
- STAI N/A
- FGEN $0.30
- Resistance Level
- STAI N/A
- FGEN $0.38
- Average True Range (ATR)
- STAI 0.00
- FGEN 0.05
- MACD
- STAI 0.00
- FGEN -0.00
- Stochastic Oscillator
- STAI 0.00
- FGEN 16.30
About STAI ScanTech AI Systems Inc. Common stock
ScanTech AI Systems Inc is developing and deploying security screening systems that protect travelers and other public members from criminals, terrorists, and other bad actors. It has developed a proprietary Computed Tomography scanning system that uses fixed-gantry technology to detect explosives, weapons, narcotics, and other contraband.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.